Choe J-Y, Park S-H, Kim S-K
Division of Rheumatology, Department of Internal Medicine, Arthritis & Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea.
Division of Rheumatology, Department of Internal Medicine, Arthritis & Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea
Lupus. 2014 Dec;23(14):1486-93. doi: 10.1177/0961203314547797. Epub 2014 Aug 14.
We investigated the association of serum and urine β2-microglobulin (β2MG) with renal involvement and clinical disease activity in systemic lupus erythematosus (SLE).
Sixty-four female patients with SLE were enrolled. We assessed SLE disease activity (SLEDAI)-2K and measured serum and urine β2MG levels, as well as complement (C3 and C4) and anti-dsDNA levels. According to the SLEDAI scores, two groups were categorized: low (0-5 of SLEDAI) and high (6-19 of SLEDAI) disease activity groups. The presence of renal involvement was determined by renal SLEDAI score. Statistical analysis was performed using Spearman's correlation analysis, Mann-Whitney U test, multivariate regression analysis, and logistic regression analysis.
Urine β2MG levels were significantly different between low and high SLEDAI groups (p = 0.001), but not for serum β2MG levels (p = 0.579). Patients with renal involvement showed higher urine β2MG levels compared to those without renal involvement (p < 0.001), but again there was not a difference in serum β2MG levels (p = 0.228). Urine β2MG was closely associated with SLEDAI (r = 0.363, p = 0.003), renal SLEDAI (r = 0.479, p < 0.001), urine protein/Cr (r = 0.416, p = 0.001), and ESR (r = 0.347, p = 0.006), but not serum β2MG (r = 0.245, p = 0.051). Urine β2MG level was identified as a surrogate for renal involvement (p = 0.009, OR = 1.017, 95% CI 1.004-1.030) and overall disease activity (p = 0.009, OR = 1.020, 95% CI 1.005-1.036).
We demonstrated that urine β2MG levels are associated with renal involvement and overall clinical disease activity in SLE.
我们研究了系统性红斑狼疮（SLE）患者血清和尿液β2微球蛋白（β2MG）与肾脏受累及临床疾病活动度之间的关联。
纳入64例女性SLE患者。我们评估了SLE疾病活动指数（SLEDAI）-2K，并检测了血清和尿液β2MG水平，以及补体（C3和C4）和抗双链DNA水平。根据SLEDAI评分，将患者分为两组：低疾病活动度组（SLEDAI为0 - 5分）和高疾病活动度组（SLEDAI为6 - 19分）。通过肾脏SLEDAI评分确定是否存在肾脏受累。采用Spearman相关性分析、Mann-Whitney U检验、多元回归分析和逻辑回归分析进行统计分析。
低SLEDAI组和高SLEDAI组的尿液β2MG水平存在显著差异（p = 0.001），但血清β2MG水平无显著差异（p = 0.579）。与无肾脏受累的患者相比，有肾脏受累的患者尿液β2MG水平更高（p < 0.001），但血清β2MG水平同样无差异（p = 0.228）。尿液β2MG与SLEDAI（r = 0.363，p = 0.003）、肾脏SLEDAI（r = 0.479，p < 0.001）、尿蛋白/肌酐（r = 0.416，p = 0.001）和血沉（r = 0.347，p = 0.006）密切相关，但与血清β2MG无关（r = 0.245，p = 0.051）。尿液β2MG水平被确定为肾脏受累（p = 0.009，OR = 1.017，95% CI 1.004 - 1.030）和总体疾病活动度（p = 0.009，OR = 1.020，95% CI 1.005 - 1.036）的替代指标。
我们证明了尿液β2MG水平与SLE患者的肾脏受累及总体临床疾病活动度相关。
